Welcome to our dedicated page for Tema Oncology ETF news (Ticker: CANC), a resource for investors and traders seeking the latest updates and insights on Tema Oncology ETF stock.
Tema Oncology ETF (CANC) reports developments tied to an exchange-traded fund focused on oncology companies and cancer therapies. News items center on fund asset growth, performance commentary, investment theme updates, and the role of biotechnology and therapy developers within the portfolio's market exposure. Coverage also includes fund risk language associated with foreign and emerging-market securities, political, economic and regulatory conditions outside the United States, and currency exposure.
Tema Oncology ETF (CANC) surpassed $100 million in assets under management two years after launch and is described as the only pure‑play oncology ETF. The fund is up 48.0% year‑to‑date in 2025 versus the S&P 500's +15.7%, placing CANC among the top 3 performers within Bloomberg's 47 healthcare and biotech ETF universe. CANC is managed by Dr. David Song MD, PhD, CFA, who has two decades of healthcare investing experience. The announcement notes oncology's rising need and characterizes oncology investing as inherently complex and risky.